In his first interview after taking the reins of the FDA’s Oncology Center of Excellence (OCE), Angelo de Claro, M.D., is ...
Takeda's long-time R&D chief Andy Plump will retire. Daiichi Sankyo beat back a $1.3 billion damage claim in a lawsuit.
Following formal sign-off from the FDA, Handa Pharmaceuticals’ branded drug reformulation strategy has paid off for a third ...
Argonaut Manufacturing Services, a CDMO specializing in aseptic fill-finish for injectable biologics and other drugs, has ...
With positive phase 3 results in hand, AbbVie is one step closer to expanding the reach of its key migraine preventative ...
In a series of moves by Switzerland-headquartered CDMOs this week, manufacturing powerhouse Lonza is doubling down on its US ...
Bayer has won first-line approval for its tyrosine kinase inhibitor, Hyrnuo, in patients with HER2-mutant non-small cell lung ...
Caris Life Sciences is signing up Hollywood legend Kevin Costner to break down the importance of early cancer detection—and ...
Following a monthslong interregnum at the U.S. Food and Drug Administration, the leadership pieces are again locking into ...
Novartis’ recent dual clinical setbacks have prompted questions from a major shareholder about the board's oversight of ...
Shifts in drug pricing and market access policies around the world have caused an “earthquake” that will reverberate for ...
In a move that at least one local HIV charity has deemed “profoundly disappointing,” England's health technology assessor NICE is currently recommending against coverage of Gilead Sciences’ landmark ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results